The antibody contract manufacturing market at an annualized rate of 12%. {claims Roots Analysis}
With over100 therapeutic monoclonal antibodies and antibody-based products in themarket

Report Keywords - Antibody Contract, Contract, Manufacturing Market, RootsAnalysis, Report


With over100 therapeutic monoclonal antibodies and antibody-based products in themarket, the demand for developing and manufacturing of such products isanticipated to increase beyond the capabilities of innovator companies alone


Roots Analysis has announced the addition of the “Antibody ContractManufacturing Market, 2020-2030” report to its listof offerings.


Althoughbiopharmaceuticals offer significant profit margins and have been proven to beeffective in treating a myriad of diseases, they are generally associated withhigh costs of development and complex manufacturing protocols; this is true forantibody-based products as well. Presently, there are a number of companiesthat claim to offer end-to-end solutions, ranging from antibody development tocommercial production. Further, prevalent trends suggest that sponsor companiesare likely to continue relying on contract service providers for variousaspects of antibody-based product development and manufacturing.


KeyMarket Insights


Over 100 CMOs presently claim to offer manufacturingservices for antibodies

Theantibody contract manufacturing market is currently dominated by the presenceof small and mid-sized companies, which represent 70% of the industrystakeholders. It is also worth highlighting that more than 55% of CMOs claim tohave the capabilities to manufacture antibodies across all scales of operation(preclinical, clinical and commercial).


More than 90% service providersare focused on the production of monoclonal antibodies

However,players based in Asia are now increasingly focusing on the development of bispecificantibodies for therapeutic use. It worth highlighting that close to 20% of theCMOs engaged in this domain claim to offer manufacturing services for bothbispecific antibodies and antibody fragments.


Formore Insightful Information -


Europe has emerged as a keymanufacturing hub for antibody-based products

Morethan 120 manufacturing facilities have been established by various players,worldwide; of these, 40% are in Europe. Additionally, 40% of the totalinstalled capacity is in Europe, followed by Asia. Some of the prominentregions in Asia include (in decreasing order of number of manufacturingfacilities) China, South Korea, India, Japan and Taiwan.


More than 90 partnership agreements have been inked between2013 and 2019

Majorityof these agreements were focused on manufacturing of various types of antibodies.Other popular types of collaboration models include process development andmanufacturing agreements (22%), product development and manufacturingagreements (10%) and licensing agreements (7%).


Multiple expansion initiatives were undertaken by CMOsbetween 2017 and 2019

Morethan 50% of such initiatives were reported to be focused on the expansion ofmanufacturing facilities, followed by building new facilities (38%). It isworth noting that close to 50% of the total number of expansion initiativeswere undertaken in Europe, of which, 25% were in the UK.


Demand for therapeutic antibodies is anticipated to grow ata CAGR of 10%, during 2020-2025

Given the fact that there are a number of antibody-basedproducts in the market, the commercial demand for antibodies is significantlyhigher than the clinical demand. Across the three major global regions, NorthAmerica represent over half of the overall global manufacturing demand forantibodies.


North America and Europe are anticipated to capture over70% of the market share by 2030

However,the market in the Asia is anticipated to grow at a relatively faster rate.Further, presently, more than 90% of the antibodies are being developed usingmammalian expression systems, and this trend is unlikely to changesignificantly in short to mid-term.


To request a sample copy of Report -


KeyQuestions Answered

§ Who are the leading CMOs engaged in the production ofantibody-based therapeutics?

§  Whatkind of partnership models are commonly adopted by stakeholders in thisindustry?

§  Whatis the annual clinical and commercial demand for antibody-based products?

§  Whatis the current installed capacity for manufacturing of antibodies?

§  Whatare the various expansion initiatives undertaken by antibody CMOs?

§ How is the current and future market opportunity likely tobe distributed across key market segments?


The USD 17 billion (by 2030) financial opportunitywithin the antibody contract manufacturing market has been analyzed across thefollowing segments:

§  Typeof Antibodies

§  MonoclonalAntibodies

§  BispecificAntibodies

§  ADCs

§  Others


§ Company Size

§ Small

§ Mid-sized

§ Large / Very Large


§  Scaleof Operation

§ Preclinical / Clinical

§ Commercial


§  Typeof expression system used

§ Mammalian

§ Microbial


§  Keygeographical regions

§  NorthAmerica

§  Europe

§  Asiaand RoW


Thereport features inputs from eminent industry stakeholders, according to whomantibody therapeutics developers are increasingly outsourcing their manufacturingoperations owing to complex nature of the overall process, as well as the highinvestments associated with setting-up in-house expertise. The report includesdetailed transcripts of discussions held with the following experts:

§  DietmarKatinger (Chief Executive Officer, Polymun Scientific)

§  DavidC Cunningham (Director, Corporate Development, Goodwin Biotechnology)

§  ClaireOtjes (Marketing Manager, Batavia Biosciences)


Theresearch covers profiles of key players that offer manufacturing services forantibodies, featuring a company overview, information on their respectiveservice portfolios, manufacturing facilities and capabilities, and an informedfuture outlook.

§  AGCBiologics

§  Aldevron


§  BoehringerIngelheim BioXcellence

§  EmergentBioSolutions

§  EurofinsCDMO

§  FUJIFILMDiosynth Biotechnologies

§  KBIBiopharma

§  Lonza

§  NittoAvecia Pharma Services

§  Novasep

§  PierreFabre

§  SamsungBioLogics

§  Synthon

§  ThermoFisher Scientific


Youmay also be interested in the following titles:

1.    Bispecific Antibody Therapeutics Market (4th Edition),2019-2030

2.    Antibody Drug Conjugates (ADCs) - Linker and Conjugation Technologies Market, 2019-2030

3.    Antibody Drug Conjugates Market (5th Edition), 2019-2030

4.    Cell Encapsulation:Focus on Therapeutics and Technologies, 2019-2030


About Roots Analysis

Roots Analysis is one of the fastest growing market researchcompanies, sharing fresh and independent perspectives in the bio-pharmaceuticalindustry. The in-depth research, analysis and insights are driven by anexperienced leadership team which has gained many years of significantexperience in this sector. If you’d like help with your growing business needs,get in touch at


Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

LinkedIn -

Twitter -